BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Orthopedic Use of BPC 157 Sports Med Review GOP lawmakers ask RFK Jr. to make FDA unleash risky peptides like BPC 157 The Niche FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog